Edition:
United Kingdom

Foundation Medicine Inc (FMI.OQ)

FMI.OQ on NASDAQ Stock Exchange Global Select Market

77.65USD
23 Feb 2018
Change (% chg)

$3.90 (+5.29%)
Prev Close
$73.75
Open
$74.60
Day's High
$77.80
Day's Low
$74.10
Volume
93,597
Avg. Vol
82,185
52-wk High
$78.50
52-wk Low
$22.40

Select another date:

Tue, Jan 16 2018

BRIEF-Foundation Medicine, Pfizer Announce Partnership To Develop Companion Diagnostics For Pfizer’S Oncology Portfolio

* FOUNDATION MEDICINE AND PFIZER ANNOUNCE BROAD PARTNERSHIP TO DEVELOP COMPANION DIAGNOSTICS FOR PFIZER’S ONCOLOGY PORTFOLIO

BRIEF-Foundation Medicine Reports Preliminary 2017 Results

* - ‍ PRELIMINARY 2017 TOTAL REVENUE OF APPROXIMATELY $152.9 MILLION, A 31% YEAR OVER YEAR INCREASE​

BRIEF-Foundation Medicine Files For Potential Mixed Shelf, Size Not Disclosed

* FOUNDATION MEDICINE INC FILES FOR POTENTIAL MIXED SHELF, SIZE NOT DISCLOSED - SEC FILING Source text: (http://bit.ly/2BO42UB) Further company coverage:

Roche's Foundation Medicine wins FDA blessing for new cancer test

ZURICH Roche on Monday said its Foundation Medicine unit won U.S. Food and Drug Administration (FDA) approval for a test to help doctors understand the genetic profile of patients' tumours and guide them to effective therapies.

Foundation's cancer gene test gets U.S. FDA and Medicare nod

CHICAGO A test from Foundation Medicine Inc that can detect cancer-causing mutations in 324 genes has won approval from the U.S. Food and Drug Administration and the Center for Medicare and Medicaid Services, the agencies said.

UPDATE 1-Foundation's cancer gene test gets U.S. FDA and Medicare nod

CHICAGO, Nov 30 A test from Foundation Medicine Inc that can detect cancer-causing mutations in 324 genes has won approval from the U.S. Food and Drug Administration and the Center for Medicare and Medicaid Services, the agencies said.

Foundation Medicine gets nod from FDA and Medicare for cancer test

CHICAGO, Nov 30 A test from Foundation Medicine Inc that can detect cancer-causing mutations in 324 genes has won simultaneous approval from the U.S. Food and Drug Administration and the Center for Medicare and Medicaid Services, the agencies said in a statement on Thursday.

BRIEF-Foundation Medicine Q3 loss per share $0.90

* Foundation Medicine announces 2017 third quarter results and recent highlights

BRIEF-Foundation Medicine receives approval from state of New York for foundation act liquid biopsy assay

* Foundation Medicine Inc - receives approval from state of New York for foundation act liquid biopsy assay Source text for Eikon: Further company coverage:

BRIEF-Foundation Medicine and Roche enters into a fifth amendment to Collaboration Agreement

* Foundation Medicine Inc - On September 8, company and Roche entered into a fifth amendment to Collaboration Agreement - SEC filing

Select another date: